Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Recruiting 2Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 5Neoplasms 4Neoplasm Metastasis 4Multiple Myeloma 3Lymphoma 3Leukemia 3Hematologic Neoplasms 3Triple Negative Breast Neoplasms 2Prostatic Neoplasms 2Ovarian Neoplasms 2Glioblastoma 2Fallopian Tube Neoplasms 2Urinary Bladder Neoplasms 1Recurrence 1Rectal Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Malignant Female Reproductive System Neoplasm 1Localized Head and Neck Carcinoma 1Leukemia, Myeloid, Acute 1Hematopoietic and Lymphoid System Neoplasm 1Gastrointestinal Neoplasms 1Fatigue 1Endometrial Neoplasms 1Depression 1Colonic Neoplasms 1Chemotherapy Effect 1Caregiver Burden 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Anxiety Disorders 1

Interventions

pembrolizumab 57Carboplatin 34Paclitaxel 24Cyclophosphamide 23Capecitabine 18sacituzumab govitecan 16Specimen Handling 15130-nm albumin-bound paclitaxel 15toripalimab 11Drug Therapy 11Biopsy 11Magnetic Resonance Spectroscopy 10Bevacizumab 10Taxes 9Epirubicin 9durvalumab 8Albumin-Bound Paclitaxel 8olaparib 7camrelizumab 7Gemcitabine 7Doxorubicin 7Docetaxel 7fludarabine 6famitinib 5Nivolumab 5Injections 5atezolizumab 4abemaciclib 4Trastuzumab 4Standard of Care 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Triple Negative Breast Neoplasms × Palliative Care × Clear all
NCT07510802 2026-04-06

Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC

Beijing Biotech

Phase 1/2 Recruiting
60 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT07486089 2026-03-20

DUAL-NK-BC

Beijing Biotech

Phase 1/2 Recruiting
60 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡